Clinical Trial News and Research

RSS

EMA's CHMP gives positive opinion for PTC Therapeutics' Translarna

PTC Therapeutics, Inc. today announced that following its request for re-examination, the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion regarding the company's application for a conditional marketing authorization of Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients aged five years and older.

23 May 2014

European Commission grants Marketing Authorization for empagliflozin for treatment of type 2 diabetes

The European Commission has granted Marketing Authorisation for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor from Boehringer Ingelheim and Eli Lilly and Company.

23 May 2014

Eliminating scar tissue, inflammation may make tumors more deadly, find researchers

New research represents a significant change in the understanding of how pancreatic cancer grows - and how it might be defeated.

23 May 2014

New database allows researchers to match old drugs for new diseases

There are thousands of drugs that silence many thousands of cancer-causing genetic abnormalities. Some of these drugs are in use now, but many of these drugs are sitting on shelves or could be used beyond the disease for which they were originally approved.

23 May 2014

Smoking cannabis associated with PTSD symptom reduction in some patients, says study

Clinical research from New Mexico supports a conclusion that smoking cannabis [marijuana] is associated with PTSD symptom reduction in some patients.

23 May 2014

International partnership of charities funds first immunotherapy clinical trial for children with neuroblastoma

Solving Kids' Cancer, the Neuroblastoma Children's Cancer Alliance (NCCA UK), and Joining Against Cancer in Kids (J-A-C-K) awarded its first grant through their INBRACED (International Neuroblastoma Research and Collaboration for Effective Delivery) initiative, which aims to improve access of promising clinical trials for children with high-risk neuroblastoma in North America, the UK and in Europe.

23 May 2014

Neovasc reports record revenues in Q1 2014

Neovasc Inc. ("Neovasc" or the "Company"), today announced financial results for the three months ended March 31, 2014. "The first quarter of 2014 was marked by major developments at Neovasc," noted Alexei Marko, chief executive officer of Neovasc.

22 May 2014

Agios Pharmaceuticals to present AG-221 Phase 1 study results at EHA meeting

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism (IEMs), today announced that new clinical data from the Phase 1 study of AG-221, an orally available, selective, potent inhibitor of the mutated IDH2 protein, will be highlighted in an oral presentation at the 19th Congress of the European Hematology Association (EHA) taking place June 12 -15, 2014 in Milan, Italy.

22 May 2014

NYU Langone Medical Center implants RNS device in brain for patients with epilepsy

NYU Langone Medical Center last month became the first hospital outside of a clinical trial site to implant a pacemaker-like device in the brain that may be a game-changer for patients with epilepsy.

22 May 2014

Study shows image fusion guided biopsy improves accuracy of prostate cancer diagnosis

A recent study by investigators from LIJ Medical Center demonstrated that using magnetic resonance imaging (MRI) in men with an elevated prostate specific antigen (PSA) resulted in a prostate cancer detection rate that was twice as high as data reported in the March 1999 Prostate journal that analyzed men undergoing the standard 12-core biopsy with an elevated PSA.

22 May 2014

St. Jude Medical's EnligHTN renal denervation system safe, effective for treating drug-resistant hypertension

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced preliminary results from the EnligHTN III study, which found the company's second-generation EnligHTN™ renal denervation system provided safe and effective therapy for patients with drug-resistant, uncontrolled hypertension six months post-procedure. The results were presented during a hot line late-breaking clinical trial session at EuroPCR 2014.

22 May 2014

SinoVeda announces positive clinical results for EffectiCal in post-menopausal women

SinoVeda Canada Inc. today announces positive clinical results for EffectiCal® from its 24-week double-blind, randomized comparative clinical trial in post-menopausal women.

22 May 2014

Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Boehringer Ingelheim today presented results of the VIVACITO® (NCT01559116) study, the first Phase 3 data to be reported from the TOviTO® clinical trial program, evaluating the effect of the fixed-dose combination of tiotropium and olodaterol (T+O FDC) delivered via the Respimat® inhaler on lung function in people with chronic obstructive pulmonary disease (COPD).

22 May 2014

Researchers explore perceptions of cancer trials on ‘International Clinical Trials Day’

A new article published by ecancermedicalscience on May 20th addresses the question of why cancer patients are afraid of participating in potentially life-saving clinical trials.

21 May 2014

Cell Science Systems launches new blood test profile for GI disorders

Distinguishing the cause of gut disorders can be complicated. Therefore, Cell Science Systems, Corp. today announced the launch of a new test to help clinicians reach a diagnosis; and, suggest dietary strategies to improve whatever gut malady a person may have.

21 May 2014

Genprex initiates Phase II clinical trial of Oncoprex for late-stage lung cancer patients

Genprex, Inc. announced today that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex in combination with erlotinib (Tarceva) for late-stage lung cancer patients.

21 May 2014

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

21 May 2014

Clinical Trial News and Research

EMA's CHMP gives positive opinion for PTC Therapeutics' Translarna

European Commission grants Marketing Authorization for empagliflozin for treatment of type 2 diabetes

Eliminating scar tissue, inflammation may make tumors more deadly, find researchers

New database allows researchers to match old drugs for new diseases

Smoking cannabis associated with PTSD symptom reduction in some patients, says study

International partnership of charities funds first immunotherapy clinical trial for children with neuroblastoma

Neovasc reports record revenues in Q1 2014

Agios Pharmaceuticals to present AG-221 Phase 1 study results at EHA meeting

NYU Langone Medical Center implants RNS device in brain for patients with epilepsy

Study shows image fusion guided biopsy improves accuracy of prostate cancer diagnosis

St. Jude Medical's EnligHTN renal denervation system safe, effective for treating drug-resistant hypertension

SinoVeda announces positive clinical results for EffectiCal in post-menopausal women

Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Researchers explore perceptions of cancer trials on ‘International Clinical Trials Day’

Cell Science Systems launches new blood test profile for GI disorders

Genprex initiates Phase II clinical trial of Oncoprex for late-stage lung cancer patients

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

BioLineRx announces financial results for Q1 2014, provides operational update

Recruiting more Hispanics to cancer clinical trials crucial to reducing health disparities

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery